Production

Ceva has made significant investments to meet demand for our vaccines

August 2014 Beam Signing event celebrated Ceva's next phase of expansion

Between 2006 and 2015, Ceva invested over $65 million to increase vaccine production capacity in our Lenexa, Kan. location. By 2017, we plan to invest an additional $40 million dollars in these facilities. During August of 2015, we broke ground on a new 35,000 sq. ft. production facility. 

Since acquiring Biomune in 2005, Ceva has added over 200,000 square feet of production space for poultry and swine vaccines and over 100,000 sq. feet of additional warehouse space in the Kansas City region to support the biologics business. 

Besides building a business domestically, vaccines produced in Lenexa are distributed to over 50 countries worldwide. During 2015, Ceva Biomune was named one of the five finalists for the Kansas Exporter of the Year award. 

Ceva has four main international sites with 19 regional production sites. R&D and industrial groups are positioned to ensure the transition from final development into full production can be managed across cross-functional teams. 

Ceva’s extensive geographic coverage means that we can provide our markets with products and services that are customized to local specifications and demand.

Ceva's production policy reflects our overall strategy to achieve the synergies and excellence driven by global plants while achieving the same standards in our plants situated close to local markets. This effort ensures maximum responsiveness for our customers.

Ground breaking August 2015

Ceva's production policy reflects our overall strategy to achieve the synergies and excellence driven by global plants while achieving the same standards in our plants situated close to local markets. This effort ensures maximum responsiveness for our customers.

Back to top